[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 20.75, "open": 20.835, "dayLow": 20.72, "dayHigh": 21.69, "regularMarketPreviousClose": 20.75, "regularMarketOpen": 20.835, "regularMarketDayLow": 20.72, "regularMarketDayHigh": 21.69, "payoutRatio": 0.0, "beta": 0.952, "forwardPE": -5.0545025, "volume": 2490675, "regularMarketVolume": 2490675, "averageVolume": 1993367, "averageVolume10days": 2980580, "averageDailyVolume10Day": 2980580, "bid": 21.22, "ask": 21.32, "bidSize": 28, "askSize": 1, "marketCap": 2949043200, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 27.34, "priceToSalesTrailing12Months": 5.146888, "fiftyDayAverage": 17.095, "twoHundredDayAverage": 17.48085, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2761640448, "profitMargins": -0.25902998, "floatShares": 118912554, "sharesOutstanding": 138258000, "sharesShort": 12937337, "sharesShortPriorMonth": 12616251, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0937, "heldPercentInsiders": 0.04443, "heldPercentInstitutions": 0.775, "shortRatio": 6.42, "shortPercentOfFloat": 0.120900005, "impliedSharesOutstanding": 138258000, "bookValue": 3.781, "priceToBook": 5.641365, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -148416992, "trailingEps": -1.2, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 4.82, "enterpriseToEbitda": -32.339, "52WeekChange": -0.13643724, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 21.33, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 43.78571, "targetMedianPrice": 38.5, "recommendationMean": 1.86667, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 898172032, "totalCashPerShare": 6.496, "ebitda": -85396000, "totalDebt": 713286016, "quickRatio": 4.667, "currentRatio": 4.868, "totalRevenue": 572976000, "debtToEquity": 137.222, "revenuePerShare": 4.395, "returnOnAssets": -0.0596, "returnOnEquity": -0.37111, "grossProfits": 572976000, "freeCashflow": -48370124, "operatingCashflow": 21845000, "grossMargins": 1.0, "ebitdaMargins": -0.14904, "operatingMargins": -5.96211, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1755899467, "regularMarketTime": 1755892801, "marketState": "CLOSED", "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.79518, "regularMarketPrice": 21.33, "longName": "Arrowhead Pharmaceuticals, Inc.", "shortName": "Arrowhead Pharmaceuticals, Inc.", "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": -1.0628215, "postMarketPrice": 21.1033, "postMarketChange": -0.22669983, "regularMarketChange": 0.58, "regularMarketDayRange": "20.72 - 21.69", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1993367, "fiftyTwoWeekLowChange": 11.76, "fiftyTwoWeekLowChangePercent": 1.2288402, "fiftyTwoWeekRange": "9.57 - 27.34", "fiftyTwoWeekHighChange": -6.01, "fiftyTwoWeekHighChangePercent": -0.21982443, "fiftyTwoWeekChangePercent": -13.6437235, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1754596800, "earningsTimestampEnd": 1754596800, "earningsCallTimestampStart": 1754598600, "earningsCallTimestampEnd": 1754598600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.2, "epsForward": -4.22, "epsCurrentYear": -0.13432, "priceEpsCurrentYear": -158.79988, "fiftyDayAverageChange": 4.2350006, "fiftyDayAverageChangePercent": 0.2477333, "twoHundredDayAverageChange": 3.8491497, "twoHundredDayAverageChangePercent": 0.22019236, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]